Amy has chaired HDR UK’s International Advisory Board since its establishment in 2020. She is the co-founder of Highlander Health, which comprises Highlander Health Institute and Highlander Health Partners. Highlander Health Institute is a public interest platform that gives philanthropic grants to test new evidence generation solutions to improve health outcomes for all; and Highlander Health Partners invests in growth-stage health care companies, optimising their success through capital and advice.
Amy previously served as principal Deputy Commissioner at the United States Food and Drug Administration (FDA) from 2019-2021. Her board roles span public companies such as Athena Health and CareDx, and private firms including insitro and Georgiamune. She also recently joined the Duke University Board of Trustees. In addition to her standard-setting and innovation work, Amy is a haematologist/oncologist, palliative medicine physician, and author of over 500 publications.
